LBL.H — Lattice Biologics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -477.58% | ||
| Return on Equity | n/a | ||
| Operating Margin | -30.96% | ||
Financial Summary
| Year End 30th Sep | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.85 | 2.74 | 1.16 | 2.19 | 2.46 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.
Directors
- Last Annual
- September 30th, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- January 1st, 1970
- Public Since
- April 1st, 1996
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 128,218,300
- Address
- 512 E. Madison Ave. Suite A1, BELGRADE, 59714
- Web
- Phone
- +1 4065702658
- Auditors
- Hay & Watson
Upcoming Events for LBL.H
Similar to LBL.H
Binovi Technologies
TSX Venture Exchange
FluroTech
TSX Venture Exchange
Health Logic Interactive
TSX Venture Exchange
H-Source Holdings
TSX Venture Exchange
SQI Diagnostics
TSX Venture Exchange
FAQ
As of Today at 19:12 UTC, shares in Lattice Biologics are trading at . This share price information is delayed by 15 minutes.
Shares in Lattice Biologics last closed at and the price had moved by -11.11% over the past 365 days. In terms of relative price strength the Lattice Biologics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -16.47% over the past year.
There is no consensus recommendation for this security.
Lattice Biologics does not currently pay a dividend.
Lattice Biologics does not currently pay a dividend.
Lattice Biologics does not currently pay a dividend.
To buy shares in Lattice Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of , shares in Lattice Biologics had a market capitalisation of .
Here are the trading details for Lattice Biologics:
- Country of listing: Canada
- Exchange: NEX
- Ticker Symbol: LBL.H
Based on an overall assessment of its quality, value and momentum Lattice Biologics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lattice Biologics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +2.39%.
As of the last closing price of , shares in Lattice Biologics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lattice Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lattice Biologics' management team is headed by:
- Guy Cook - CEO
- Donna Medina - CFO
- Kevin Loud - IND